|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Exploring this novel combined approach in the clinic to treat glioblastoma patients with MGMT promoter-unmethylated tumors is warranted.
|
30537486 |
2019 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the frequency of pseudoprogression of glioblastoma in Chinese patients receiving concomitant chemoradiotherapy and investigate its association with pseudoprogression and tumour molecular marker O(6)-methylguanine-DNA methyltransferase promoter methylation status.
|
22665686 |
2012 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis revealed age, Karnofsky performance score, extent of tumor resection, first-line treatment, year of diagnosis, and MGMT promoter methylation status were associated with survival in patients with IDH1(R132H) -nonmutant glioblastoma.
|
27088883 |
2016 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, there are still other factors that affected the prognosis for the glioblastoma patients with similar MGMT methylation status.
|
27588397 |
2016 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alterations in MGMT play a critical role in the development of several types of cancer, including glioblastoma, lung cancer, and colorectal cancer.
|
24801985 |
2014 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
|
26935578 |
2016 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Alternative strategies need to be considered for patients with progressive glioblastoma without MGMT promoter methylation.
|
25655102 |
2015 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical data (age, sex, extent of surgical resection), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and pre-operative T2WI of 113 pathologically confirmed glioblastoma patients (from our institution, n = 61; from the Cancer Imaging Archive, n = 52) were retrospectively reviewed.
|
31150499 |
2019 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%.
|
31173153 |
2020 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although this data is from a retrospective analysis using small number of patients, the study might indicate that concomitant use of temozolomide with radiotherapy is a crucial step in the standard treatment for glioblastoma patients with MGMT promoter methylation.
|
23377829 |
2013 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We applied real-time semi-quantitative methylation-specific polymerase chain reaction (SQ-MSP) of the MGMT gene promoter region to 84 glioblastoma patients.
|
29963232 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Biopsy resulted in a diagnosis of glioblastoma with methylated MGMT promoter and wild-type IDH1.
|
24473978 |
2014 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinically, chemoconditioning with BCNU and TMZ should facilitate engraftment of MGMT(P140K)-modified cells while providing antitumor activity for patients with poor prognosis glioblastoma or alkylating agent-sensitive tumors, thereby supporting dose-intensified chemotherapy regimens.
|
22627392 |
2012 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MGMT promoter methylated tumors occur more frequently in the left temporal lobe, in young patients with glioblastoma, in IDH1 mutant tumors, in tumors having the proneural gene expression subtype, and in tumors lacking loss of PTEN occurring most frequently in the frontal lobe.
|
22997168 |
2013 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The Clinical Significance of O<sup>6</sup>-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis.
|
29619003 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the clinical significance of SNPs in the MGMT promoter region of glioblastoma.
|
29036186 |
2017 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter is predictive for treatment response in glioblastoma patients.
|
31167648 |
2019 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
|
19514084 |
2009 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although methylation of the O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) gene promoter predicts response to temozolomide in patients with glioblastoma, no consensus exists as to which assay is best for its detection.
|
30343277 |
2018 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is no consensus recommendation regarding the best available treatment for patients over age 70 with glioblastoma; however, multiple studies have shown molecular characterization of glioblastoma in this group-particularly MGMT promoter methylation status-to be valuable in treatment decision making.
|
28620898 |
2017 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
|
31413318 |
2019 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylation of the CpG island in the MGMT promoter region is a frequent event in several cancer types including colorectal cancer, lung cancer, lymphoma, and glioblastoma.
|
19789298 |
2009 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
|
25078279 |
2014 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
|
28302331 |
2017 |
|
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
|
27143690 |
2016 |